Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30673
Low Molecular Weight Heparin during Pregnancy

Authors: Merita Dauti, Sihana Ahmeti Lika, Ledjan Malaj


The objective of this study is to analyze the prophylactic usage of low molecular weight heparin (LMWH) along pregnancy and the correlation between their usage and month/week of pregnancy, in the Department of Gynecology and Obstetrics, at Clinical Hospital in Tetovo. A retrospective study was undertaken during 01 January – 31 December 2012. Over of one year, the total number of patients was 4636. Among the 1447 (32.21%) pregnant women, 298 (20.59%) of them were prescribed LMWH. The majority of patients given LMWH, 119 (39.93%) were diagnosed hypercoagulable. The age group with the highest attendance was 25- 35, 141 patients (47.32%). For 195 (65.44%) patients, this was their first pregnancy. Earliest stage of using LMWH was the second month of pregnancy 4 (1.34%) cases. The most common patients were 70 women along the seventh month (23.49%), followed by 68 in the ninth month of pregnancy (22.81%). Women in the 28th gestational week, were found to be the most affected, a total of 55 (78.57%) were in that week. Clexane 2000 and Fraxiparine 0.3 were the most common for which low molecular weight heparin was prescribed. The number of patients which received Clexane 2000 was 84 (28.19%), followed by those with Fraxiparine 0.3 81 (27.18%). The administration of LMWH is associated with long hospitalization (median 14,6 days).

Keywords: Pregnant Women, hypercoagulable state, month of pregnancy, low molecular weight heparin

Digital Object Identifier (DOI):

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 2237


[1] A. H.James, “Thrombotic Challenges Beyond Hematology (Book style),” Durham, North Carolina, 2009, pp. 277-285
[2] M. R. Toglia, J. G. Weg, “Venous thromboembolism durimg pregnancy” The New England Journal of Medicine, vol. 335, no. 2, pp. 108-114, July 1996
[3] V .A. Rosenberg, C. J. Lockwood, “Thromboembolism in Pregnancy,” Obstetrics and Gynecology Clinics, vol. 34, no. 3, pp. 481-500, Sep. 2007
[4] P. E. Marik, L. A. Plante, “Venous Thromboembolic Disease and Pregnancy,” New England Journal of Medicine, vol. 359, pp. 2025- 2033, Nov 2008
[5] M. M.W. Koopman, et al. “Treatmant of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Moleculare-Weight-Heparin Administered at Home,” New England Journal of Medicine, vol. 334, pp. 682-687, March 1996
[6] J. I. Weitz, “Low-Molecular-Weight-Heparins,” The” New England Journal of Medicine, vol. 337, pp. 688-699, Sep.1997
[7] M. Levine, “A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis,” The New England Journal of Medicine, vol. 334, pp. 677-681,Nov 2008